For instance, cancer cells addicted to continuous protein production are particularly vulnerable to CDK9 inhibition.177 On the other hand, CDK9 inhibition represents a potential therapeutic strategy against chemotherapy-persistent tumor cells for its ability to interfere with diapause-like adaptation, necessary for persistent cells to survive the pressure of chemotherapy.712 However, careful dosing and treatment schedules are needed to manage toxicities and optimize therapeutic windows. This evidence concerns the gene CDK9 and neoplasm.